Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.

  • Authors:
    • A Riccardi
    • C Tinelli
    • S Brugnatelli
    • P Pugliese
    • V Giardina
    • M Giordano
    • M Danova
    • A Richetti
    • S Fava
    • E Rinaldi
    • V Fregoni
    • G Trotti
    • A Poli
  • View Affiliations

  • Published online on: April 1, 2000     https://doi.org/10.3892/ijo.16.4.769
  • Pages: 769-845
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In metastatic breast cancer (MBC) doubling the epirubicin (EPI) dose intensity (DI) within the FEC (5-fluorouracil, EPI, cyclophosphamide) regimen could increase the response rate (RR) and ameliorate the quality of life (QoL) over standard FEC. From May, 1995, 74 consecutive patients with MBC were randomly treated with 6 courses of two FEC regimens containing 60 (60FEC) or 120 (120FEC, supported by primary G-CSF) mg/m2 of EPI. Drugs were administered every 21 days. The QoL was assessed over and after treatment by the EORTC QLQ-C30 (VER 2.0) and QLQ-BR23 questionnaires, compiled by the patient, and the Spitzer's QL-index, compiled by the physician. The study was prematurely closed in May, 1997, due to RR and QoL data of 4th interim analysis. The delivered EPI DI was 20.0 and 37.9 mg/m2/week in 60- and in 120FEC, respectively. Among the two regimens, there was no statistically significant difference in RR or in improvement of baseline overall QoL. With respect to 60FEC patients, the 120FEC patients had longer time to progression (19.2 vs 13.1 mos, p=0.04). Over baseline, the 120- but not the 60FEC patients had significantly greater pain decrease and lower deterioration of body image. In MBC, both 60- and 120FEC regimens furnished the same RR and improvement in overall baseline QoL. With respect to 60FEC patients, the 120FEC patients experienced longer time to progression. Over baseline, pain decrease and preservation of body image were also greater in these patients.

Related Articles

Journal Cover

April 2000
Volume 16 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Riccardi, A., Tinelli, C., Brugnatelli, S., Pugliese, P., Giardina, V., Giordano, M. ... Poli, A. (2000). Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.. International Journal of Oncology, 16, 769-845. https://doi.org/10.3892/ijo.16.4.769
MLA
Riccardi, A., Tinelli, C., Brugnatelli, S., Pugliese, P., Giardina, V., Giordano, M., Danova, M., Richetti, A., Fava, S., Rinaldi, E., Fregoni, V., Trotti, G., Poli, A."Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.". International Journal of Oncology 16.4 (2000): 769-845.
Chicago
Riccardi, A., Tinelli, C., Brugnatelli, S., Pugliese, P., Giardina, V., Giordano, M., Danova, M., Richetti, A., Fava, S., Rinaldi, E., Fregoni, V., Trotti, G., Poli, A."Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.". International Journal of Oncology 16, no. 4 (2000): 769-845. https://doi.org/10.3892/ijo.16.4.769